Tenderwize
Retour à la recherche

Open house drug discount agreements multienzyme (Lipase, Protease etc.), ATC A09AA02

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Feb 03, 2028 · 523 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Multienzyme (Lipase, Protease etc.), ATC A09AA02

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

25 / 100

Facteurs de risque

No guaranteed sales; actual revenue depends on prescription volumes and market penetration.

Monthly cut-off deadlines require careful timing; missing the 3rd may delay contract start by up to two months.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Non-exclusive drug discount agreements for multienzyme products (ATC A09AA02) with AOK Bayern.
  • Open-house model: all eligible pharmaceutical companies may join on identical terms.
Afficher le résumé complet

Open-house model for non-exclusive drug discount agreements (Rabattverträge) for multienzymes (Lipase, Protease etc.), ATC A09AA02, with AOK Bayern. The procedure is not a competitive tender but a continuous open-house where any eligible pharmaceutical company can enter identical, non-negotiable agreements. The contract term is from 1 April 2026 to 31 March 2028, with possible early termination if superseded by regular discount contracts. There is no estimated value, and no award criteria since all eligible participants are accepted. The key eligibility requirement is a signed declaration of reliability. Submissions can be in paper (two copies) or electronically with a qualified electronic signature.

Risques

No guaranteed sales; actual revenue depends on prescription volumes and market penetration.

Monthly cut-off deadlines require careful timing; missing the 3rd may delay contract start by up to two months.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible to participate.

Administrative

  • Signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
  • Contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be signed and submitted in duplicate (paper) or with qualified electronic signature.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house drug discount agreements multienzyme (Lipase, Protease etc.), ATC A09AA02

Non-exclusive discount agreements for pharmaceutical products containing multienzymes (Lipase, Protease etc.), ATC A09AA02. The agreement is open to all pharmaceutical companies meeting the eligibility criteria. Contracts start on the first of the month following complete submission, with a monthly cut-off on the 3rd. The latest joining date is 3 February 2028.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Mar 2026 - Mar 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Feb 03, 2028

Détails de la procédure

Date de publication
15 Feb 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
107164-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30